Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of June 2018, with the specific notification dated May 25, 2018. The filing announces the implementation of a share buy-back programme authorized by the General Meeting on May 12, 2016.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the share repurchase programme:
- Maximum Shares to Repurchase: 431,000 ordinary shares (approximately 0.14% of share capital).
- Total Purchase Price Cap: Up to 39 million Euro (approximately 46.5 million U.S. Dollar), excluding ancillary transaction costs.
- Repurchase Period: May 28, 2018, to June 20, 2018.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. The primary event is the initiation of the share buy-back programme to neutralize dilution from the Stock Option Plan 2011.
Guidance, Outlook, and Management Commentary
Purpose of Buy-back: The repurchased shares will be used solely to reduce registered share capital by cancellation, specifically to offset dilution from the Stock Option Plan 2011.
Trading Conditions:
- Shares will be repurchased via the XETRA trading system.
- Price limits: The price per share must not deviate by more than 10% from the market price determined by the opening auction on the trading day.
- Volume limits: Purchases are capped at 25% of the average daily volume based on the preceding 20 trading days.
- Execution: A credit institution will execute the programme independently of the Company.
Disclosure: Transaction details will be published on the company website within seven trading days of execution.
Investor Verification Checklist
- Verify the actual volume and average price of shares repurchased once the programme concludes on June 20, 2018.
- Confirm the impact of the share cancellation on the total number of outstanding shares and earnings per share.
- Review the company's website for the detailed transaction reports required to be published within seven trading days of execution.
- Note that this filing contains no operational or financial performance data for the period; refer to the most recent Form 20-F or quarterly reports for those metrics.